Chemiluminescence immunoassay and nucleic acid testing for TTI screening: A narrative review of performance, complementarity, and blood safety

Main Article Content

Abdul Karim

Keywords

blood donors, hepatitis B, hepatitis C, HIV infections, serologic tests

Abstract

Introduction: Screening for transfusion-transmitted infections (TTIs) is essential to blood safety. Chemiluminescence immunoassay (ChLIA) enables automated, high-throughput serological screening, whereas nucleic acid testing (NAT) detects viral nucleic acids and reduces the diagnostic window period. This review aimed to evaluate ChLIA for screening hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and syphilis; compare its performance with NAT for HBV, HCV, and HIV; and examine the implications for transfusion safety.

Methods: A directed narrative review was conducted by a single reviewer (A.K.). PubMed was searched on September 7, 2026, using a predefined, reproducible search strategy. Supplementary searches included peer-reviewed journals, reference lists, World Health Organization publications, and official Indonesian regulatory sources. Studies were prioritized according to their relevance to blood donor screening, ChLIA–NAT comparisons, residual transfusion risk, occult HBV infection, and Indonesian regulatory requirements. Uncertain records underwent full-text assessment.

Results: The included studies varied in assay characteristics, screening markers, donor populations, and reference standards, precluding meaningful pooling or generalization of diagnostic accuracy estimates. ChLIA and NAT detect distinct biological targets, with their relative contributions to blood safety influenced by pathogen epidemiology, residual risk, regulatory requirements, and healthcare resources. Findings from Shahin et al. and the Indonesian study are presented with their respective denominators and discordant testing patterns to ensure appropriate interpretation.

Conclusion: ChLIA demonstrates high diagnostic performance, although accuracy varies across assays and clinical settings. Its complementary use with NAT may enhance transfusion safety when guided by pathogen-specific residual risk, local epidemiology, regulatory requirements, and healthcare capacity. Both approaches should be integrated within comprehensive quality assurance and hemovigilance systems.

Abstract 54 | PDF Downloads 28

References

1. de Jonge LL, Wiersum-Osselton JC, Bokhorst AG, Schipperus MR, Zwaginga JJ. Haemovigilance: current practices and future developments. Ann Blood. 2022;7:23. Available from: http://dx.doi.org/10.21037/aob-22-2
2. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Nomor 11 Tahun 2025 tentang Standar Kegiatan Usaha dan Standar Produk/Jasa pada Penyelenggaraan Perizinan Berusaha Berbasis Risiko Subsektor Kesehatan [Internet]. 2025. Available from: https://jdih.kemkes.go.id/documents/peraturan-menteri-kesehatan-nomor-11-tahun-2025
3. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 91 Tahun 2015 tentang Standar Pelayanan Transfusi Darah [Internet]. 2016. Available from: https://repository.kemkes.go.id/book/690
4. Badan Pengawas Obat dan Makanan. Peraturan Badan Pengawas Obat dan Makanan Nomor 11 Tahun 2025 tentang Standar Cara Pembuatan Obat yang Baik di Unit Pengelola Darah dan Bank Plasma [Internet]. 2025. Available from: https://jdih.pom.go.id/
025/312351bff07989769097660a56395065
5. Shahin D, Aly R, Ghannam M, Khaled O, Sadeq M, Elzeiny A, et al. A comparative analysis between NAT and chemiluminescence in detection of transfusion transmitted viruses in two main university blood transfusion centers. Sci Rep. 2025;15:20109. Available from: http://dx.doi.org/10.1038/s41598-025-03506-6
6. World Health Organization. Screening donated blood for transfusion-transmissible infections : recommendations [Internet]. 2009. Available from: https://www.who.int/publications/i/item/screening-donated-blood-for-transfusion-transmissible-infections-recommendations
7. Tiwari AK, Upadhyay AP, Arora D, Wadhwa T, Aggarwal G, Pabbi S, et al. Head-to-head comparison of Enzyme Linked Immunosorbent Assay (ELISA) and Enhanced Chemiluminescence Immunoassay (ECLIA) for the detection of Transfusion Transmitted Disease (TTD) Markers; HIV, HCV and HBV in blood donors, in India. J Virol Methods. 2020;285:113962. Available from: http://dx.doi.org/10.1016/j.jviromet.2020.113962
8. Sommese L, Sabia C, Paolillo R, Parente D, Capuano M, Iannone C, et al. Screening tests for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus in blood donors: Evaluation of two chemiluminescent immunoassay systems. Scand J Infect Dis. 2014;46(9):660–4. Available from: http://dx.doi.org/10.3109/00365548.2014.926564
9. Kopacz A, Kubicka-Russel D, Liszewski G, Bukowska A, Samek S, Malka D, et al. Evaluation and experience from routine use of chemiluminescence assays for serological screening of blood and plasma donations on the Alinity s system and the Alinity i system, two new fully-automated immunoassay systems in Poland. Pract Lab Med. 2024;39:e00364. Available from: http://dx.doi.org/10.1016/j.plabm.2024.e00364
10. World Health Organization. Guidelines on estimation of residual risk of HIV, HBV or HCV infections via cellular blood components and plasma, Annex 4, TRS No 1004 [Internet]. 2017. Available from: https://www.who.int/publications/m/item/annex-4-trs-no-1004
11. Faddy HM, Osiowy C, Custer B, Busch M, Stramer SL, Adesina O, et al. International review of blood donation nucleic acid amplification testing. Vox Sang. 2024;119(4):315–25. Available from: http://dx.doi.org/10.1111/vox.13592
12. Arcot PJ, Pandey HC, Coshic P, Jain P, Kumar S, Chakroborty S. Comparative evaluation of ADVIA Centaur® XP chemiluminescence system for screening of HBV, HCV, HIV and syphilis in Indian blood donors. Transfus Apher Sci. 2022;61(2):103318. Available from: http://dx.doi.org/10.1016/j.transci.2021.103318
13. Hartaty S, Gantini RE, Nuryadin A, Wulandari R. Evaluation of a chemiluminescence immunoassay analyser and anti-HCV, HBsAg and syphilis immunoassays in central blood transfusion services Indonesian Red Cross [poster abstract P059]. Vox Sang. 2023;118(Suppl 1):148. Available from: https://doi.org/10.1111/vox.13433_1
14. Ahmad IW, Rini DP. Correlation and Discrepancy Between Serology and Molecular Test in Transfusion-Transmitted Infection in Surabaya Blood Donor Unit. Indones J Clin Pathol Med Lab. 2026;32(2):148–52. Available from: http://dx.doi.org/10.24293/ijcpml.v32i2.2877
15. Muhammadiy NS, Senjarini K, Fajrin FA, Velavan TP, Song LH, My TN. Occult Hepatitis B infection (OBI) in Indonesia: A Systematic Review. J Agromedicine Med Sci. 2025;11(3):130–8. Available from: https://doi.org/10.19184/ams.v11i3.53733
16. Trevethan R. Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice. Front Public Health. 2017;5:307. Available from: http://dx.doi.org/10.3389/fpubh.2017.00307
17. Sarker T, Katz LM, Bloch EM, Goel R. Blood Product (Donor) Noninfectious and Infectious Testing and Modification. Clin Lab Med. 2021;41(4):579–98. Available from: http://dx.doi.org/10.1016/j.cll.2021.07.002
18. Chozie NA, Satiti MA, Sjarif DR, Oswari H, Ritchie NK. The impact of nucleic acid testing as a blood donor screening method in transfusion-associated hepatitis C among children with bleeding disorders in Indonesia: a single-center experience. Blood Res. 2022;57(2):129–34. Available from: http://dx.doi.org/10.5045/br.2022.2021219